CSIR-IICT, 101 Therapeutics collaborate for COVID drug trials
The agreement will be for 3 years tenure and on successful completion of the clinical trials, this drug would prove to be highly appropriate and effective in treatment of covid-19 and also help combating future pandemics.
Hyderabad: CSIR-Indian Institute of Chemical Technology (CSIR-IICT) has entered into an agreement with 101 Therapeutics Limited, Israel, to conduct clinical trials of a novel Covid-19 drug with enormous therapeutic potential.
The collaboration is the result of the initiative taken by CSIR in connecting their labs working in healthcare theme with Israel’s nominated industries to explore synergies and jointly contribute innovative solutions that can be affordable & accessible to Indian population, a release said on Saturday.
CSIR-IICT will be the knowledge partner for the clinical trial study, offering expert guidance, monitoring, and smooth execution of the programme with the CRO identified by 101 Therapeutics Limited.
The agreement will be for 3 years tenure and on successful completion of the clinical trials, this drug would prove to be highly appropriate and effective in treatment of covid-19 and also help combating future pandemics.
Dr Srinivasa Reddy, Director, CSIR-IICT, and Dr. Sistla Ramakrishna, Chief Scientist & Project Leader, joined the meeting online, and Dr. D Shailaja, Chief Scientist & Chair, Business Development & Research Management, signed the agreement on behalf of CSIR-IICT.
Alec Goldberg signed the agreement from 101 Therapeutics Limited, in the presence of Michael Goldberg, who attended the meeting online from Israel.
The MoU was exchanged with Osher Shapira, Head, Dual Use unit of DDR&D, in the presence of Union Minister Dr. Jitendra Singh and Dr. Kalaiselvi, DG, CSIR.
Dr Reddy expressed his happiness at entering into the first engagement under this initiative and assured that CSIR-IICT would always be at the forefront of facilitating access to state-of-the-art healthcare technologies to Indians.
Read also: Nosch Labs, CSIR-IICT ink pact for transfer of process knowhow to make anti-Covid drug 2-DG
Next Story